IBRXHealthcare · BiotechnologyThe 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $12 — +46.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 2 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +46.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 21 May 2026 | BTIG | Reiterates | Buy | — |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 12 Mar 2026 | BTIG | Assumes | Buy | $13 |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 23 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2026 | BTIG | Maintains | Buy | — |
| 23 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, ImmunityBio, Inc. returned +245.1% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 6% of US stocks
Cheaper than 97% of US stocks
Cheaper than 93% of US stocks
Higher than 92% of US stocks
Higher than 83% of US stocks
Higher than 99% of US stocks
Higher than 13% of US stocks
Higher than 99% of US stocks
Higher than 95% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ImmunityBio, Inc. has a market value of $8.3B and an enterprise value of $9.2B.
Revenue in the twelve months to 30 June 2026: $165.8M. The latest quarter grew 93.9% year on year.
Net income over the same four quarters: −$992.4M, a −598.6% net margin.
Diluted earnings per share, trailing twelve months: $−0.97.
Free cash flow in the twelve months to 30 June 2026: −$288.5M.
Trailing P/E: −20.7×; forward P/E: −62.1× — the forward figure prices analyst consensus estimates, not reported earnings.
ImmunityBio, Inc. employs 684 people — $242K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ImmunityBio reported earnings roughly 30 days ago, and its stock has risen 9.7% since that report. The article reflects on what may come next for the company's shares following the earnings release.
Why it matters — An IBRX watcher would care because the 9.7% gain since the last earnings report signals how the market has responded to the company's latest results.
A Seeking Alpha article discusses ImmunityBio's ANKTIVA FDA approval for BCG-unresponsive NMIBC and its pipeline expansion potential, noting that current valuation reflects success in bladder cancer while assigning limited value to systemic immunotherapy potential in NSCLC and other cancers. It highlights phase 3 NSCLC data and BCG-naïve bladder cancer trial results as near-term catalysts.
Why it matters — IBRX watchers would care because these upcoming trial results and pipeline opportunities could significantly affect how the company's prospects are valued.
ImmunityBio has appointed Dr. Jim Yong Kim, former President of the World Bank and a global health leader, as Vice Chairman. He will serve in a newly created Office of the Executive Chairman, focusing on strengthening the company's international and global relationships.
Why it matters — This appointment brings a prominent global health and leadership figure to ImmunityBio's executive team, which could enhance the company's international partnerships and credibility.
ImmunityBio beat Q2 earnings and revenue estimates, with record Anktiva sales and continued adoption fueling growth. The company has additional regulatory milestones ahead.
Why it matters — The earnings and revenue beat, driven by record Anktiva sales and adoption, signals strong commercial momentum and may focus watchers on upcoming regulatory milestones.
ImmunityBio reported a Q2 loss of $0.08 per share, beating the Zacks Consensus Estimate of a $0.09 loss and narrowing from a $0.10 per-share loss a year ago.
Why it matters — The narrower-than-expected loss signals improved financial performance, which IBRX watchers would view as a positive earnings surprise.
The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 52 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, ImmunityBio, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +46.7% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 52 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
ImmunityBio, Inc. returned +245.1% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?". ImmunityBio reported earnings roughly 30 days ago, and its stock has risen 9.7% since that report. The article reflects on what may come next for the company's shares following the earnings release.
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.
CEO Mr. Richard Gerald Adcock · 684 employees · United States · https://immunitybio.com
